Selexipag Patent Expiration
Selexipag is Used for treating pulmonary arterial hypertension. It was first introduced by Actelion Pharmaceuticals Us Inc
Selexipag Patents
Given below is the list of patents protecting Selexipag, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Uptravi | US10821108 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | Dec 01, 2036 | Actelion |
| Uptravi | US10828298 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide | Dec 01, 2036 | Actelion |
| Uptravi | US8791122 | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same | Aug 01, 2030 | Actelion |
| Uptravi | US9284280 | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | Jun 25, 2030 | Actelion |
| Uptravi | US9173881 | Therapeutic compositions containing macitentan | Aug 12, 2029 | Actelion |
| Uptravi | US7205302 | Heterocyclic compound derivatives and medicines | Oct 31, 2026 | Actelion |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Selexipag's patents.
Latest Legal Activities on Selexipag's Patents
Given below is the list recent legal activities going on the following patents of Selexipag.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828298 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10821108 |
| Court Processing Terminated | 02 Apr, 2024 | US7205302 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284280 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Apr, 2023 | US9173881 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jan, 2022 | US8791122 |
| Patent Term Extension Certificate Critical | 12 Nov, 2021 | US7205302 |
| Notice of Final Determination -Eligible | 09 Mar, 2021 | US7205302 |
| Case Docketed to Examiner in GAU Critical | 06 Jan, 2021 | US7205302 |
| Patent Issue Date Used in PTA Calculation Critical | 10 Nov, 2020 | US10828298 |
Selexipag's Family Patents
Explore Our Curated Drug Screens
Selexipag Generic API Manufacturers
Several generic applications have been filed for Selexipag. The first generic version for Selexipag was by Zydus Lifesciences Global Fze and was approved on Dec 21, 2022. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Oct 11, 2023.
Given below is the list of companies who have filed for Selexipag generic, along with the locations of their manufacturing plants worldwide.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Selexipag. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
| 0.4MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
| 0.6MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
| 0.8MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
| 1.4MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
| 1.6MG | tablet | Prescription | ORAL | AB | Oct 11, 2023 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
2. ZYDUS LIFESCIENCES
Zydus Lifesciences Global Fze has filed for 8 different strengths of generic version for Selexipag. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 0.4MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 0.6MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 0.8MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 1MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 1.2MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 1.4MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
| 1.6MG | tablet | Discontinued | ORAL | N/A | Dec 21, 2022 |
Manufacturing Plant Locations New
Zydus Lifesciences's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Zydus Lifesciences as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||